Harwin Peter Evan's Form 4 filing
Zenas BioPharma, Inc. (ZBIO) · filed Sep 16, 2024
- Accession no.
- 0001104659-24-100330
- Filed
- Sep 16, 2024, 8:54 PM ET
- Trade date
- Sep 12-16, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 5 derivative transactions. Open-market purchases total $5.10M. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0001104659-24-100766 (Sep 17, 2024). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harwin Peter EvanCIK 0001663607 | Director |
| Fairmount Healthcare Fund II L.P.CIK 0001769651 | Director |
| Fairmount Funds Management LLCCIK 0001802528 | Director |
| Kiselak TomasCIK 0001830177 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2024 | Common Stock | CConversionAcquired | +41,130 | – | – | 41,140 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionAcquired | +252,890 | – | – | 294,020 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionAcquired | +709,794 | – | – | 1,003,814 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionAcquired | +301,077 | – | – | 1,304,891 | Indirect | |
| Sep 16, 2024 | Common Stock | PPurchaseAcquired | +300,000 | $17.00 | +$5,100,000 | 1,604,891 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2024 | Common Stock | CConversionDisposed | −41,130 | – | – | 0 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionDisposed | −252,890 | – | – | 0 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionDisposed | −709,794 | – | – | 0 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionDisposed | −301,077 | – | – | 0 | Indirect | |
| Sep 12, 2024 | Common Stock | AGrant or awardAcquired | +37,000 | $0.00 | $0 | 37,000 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.